In the HER2-positive GC patients, high-expression EBF1 (HR = 1.5, 95% CI = 1.03–2.18, P=0.033), EBF2 (HR = 1.92, 95% CI = 1.31–2.80, P<0.001), and EBF4 (HR = 1.54, 95% CI = 1.06–2.24, P=0.024, Figure 5B) linked with poor prognosis; similar results were observed in HER2-negative GC patients, EBF1 (HR = 1.44, 95% CI = 1.11–1.89, P=0.007), EBF2 (HR = 1.67, 95% CI = 1.28–2.19, P<0.001), and EBF4 (HR = 1.78, 95% CI = 1.36–2.33, P<0.001, Figure 5C). Here, EBF2 is linked to gastric cancer.